Alkermes Plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and … Read more
Market Cap & Net Worth: Alkermes Plc (ALKS)
Alkermes Plc (NASDAQ:ALKS) has a market capitalization of $4.61 Billion ($4.61 Billion) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #3106 globally and #2088 in its home market, demonstrating a -2.81% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Alkermes Plc's stock price $27.65 by its total outstanding shares 166649934 (166.65 Million).
Alkermes Plc Market Cap History: 2015 to 2026
Alkermes Plc's market capitalization history from 2015 to 2026. Data shows change from $13.23 Billion to $4.61 Billion (-7.51% CAGR).
Index Memberships
Alkermes Plc is a constituent of 7 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Biotechnology
BTK
|
$879.22 Billion | 0.48% | #22 of 30 |
|
Dow Jones Biotechnology
DJUSBT
|
$1.15 Trillion | 0.37% | #17 of 39 |
|
ARCA Pharmaceutical
DRG
|
$2.77 Trillion | 0.15% | #13 of 24 |
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.19% | #71 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.01% | #382 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 0.28% | #46 of 263 |
|
S&P Small-Cap 600 Index
SML
|
$1.36 Trillion | 0.38% | #78 of 602 |
Weight: Alkermes Plc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Alkermes Plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Alkermes Plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.16x
Alkermes Plc's market cap is 3.16 times its annual revenue
1.02x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
19.29x
Alkermes Plc's market cap is 19.29 times its annual earnings
10.35x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $9.26 Billion | $745.69 Million | -$208.44 Million | 12.42x | N/A |
| 2017 | $9.12 Billion | $903.37 Million | -$157.94 Million | 10.10x | N/A |
| 2018 | $4.92 Billion | $1.09 Billion | -$139.31 Million | 4.49x | N/A |
| 2019 | $3.40 Billion | $1.17 Billion | -$196.62 Million | 2.90x | N/A |
| 2020 | $3.32 Billion | $1.04 Billion | -$110.86 Million | 3.20x | N/A |
| 2021 | $3.88 Billion | $1.17 Billion | -$48.17 Million | 3.30x | N/A |
| 2022 | $4.35 Billion | $1.11 Billion | -$158.27 Million | 3.92x | N/A |
| 2023 | $4.62 Billion | $1.66 Billion | $355.76 Million | 2.78x | 12.99x |
| 2024 | $4.79 Billion | $1.56 Billion | $367.07 Million | 3.08x | 13.06x |
| 2025 | $4.66 Billion | $1.48 Billion | $241.66 Million | 3.16x | 19.29x |
Competitor Companies of ALKS by Market Capitalization
Companies near Alkermes Plc in the global market cap rankings as of March 18, 2026.
Key companies related to Alkermes Plc by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Alkermes Plc Historical Marketcap From 2015 to 2026
Between 2015 and today, Alkermes Plc's market cap moved from $13.23 Billion to $ 4.61 Billion, with a yearly change of -7.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.61 Billion | -1.18% |
| 2025 | $4.66 Billion | -2.71% |
| 2024 | $4.79 Billion | +3.68% |
| 2023 | $4.62 Billion | +6.16% |
| 2022 | $4.35 Billion | +12.34% |
| 2021 | $3.88 Billion | +16.59% |
| 2020 | $3.32 Billion | -2.21% |
| 2019 | $3.40 Billion | -30.87% |
| 2018 | $4.92 Billion | -46.08% |
| 2017 | $9.12 Billion | -1.53% |
| 2016 | $9.26 Billion | -29.98% |
| 2015 | $13.23 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Alkermes Plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.61 Billion USD |
| MoneyControl | $4.61 Billion USD |
| MarketWatch | $4.61 Billion USD |
| marketcap.company | $4.61 Billion USD |
| Reuters | $4.61 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.